Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2017 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.77%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reacted negatively, declining by 0.77%. The lack of revenue data and guidance may have contributed to investor caution, as they seek clearer indicators of future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.06	N/A	+12.47%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their research and development efforts. They acknowledged the competitive landscape but are optimistic about future prospects.

Management highlighted ongoing developments in their pipeline.

They expressed confidence in their long-term strategy despite current challenges.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.77%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.77%

Key numbers

Management commentary